A program that addressed the additional toxicity studies under U.S. GLP requirements and related materials requested by the FDA in connection with the U.S. IND application for F351, leading to authorization to initiate a Phase I trial.
Companies1How many companies write about this.
Threads4One company can carry more than one thread here.